Analyst Price Target is GBX 1,725
▲ +14.58% Upside Potential
This price target is based on 4 analysts offering 12 month price targets for Hikma Pharmaceuticals in the last 3 months. The average price target is GBX 1,725, with a high forecast of GBX 2,300 and a low forecast of GBX 1,400. The average price target represents a 14.58% upside from the last price of GBX 1,505.50.
Current Consensus is
The current consensus among 4 investment analysts is to hold stock in Hikma Pharmaceuticals. This rating has held steady since November 2021, when it changed from a Buy consensus rating.
Hikma Pharmaceuticals PLC develops, manufactures, markets, and sells a range of generic, branded, and in-licensed pharmaceutical products. The company offers its products in solid, semi-solid, liquid, and injectable final dosage forms. It operates through three segments: Injectables, Generics, and Branded. The Injectables segment provides generic injectable products primarily for use in hospitals. The Generics segment offers oral and other non-injectable generic products for the retail market. The Branded segment offers branded generics and in-licensed products to retail and hospital markets. The company provides its products in various therapeutic areas, including anti-infective, cardiovascular, central nervous system, diabetes, oncology, pain management, and respiratory. It operates in the United Kingdom, the United States, the Middle East, North Africa, Europe, and internationally. The company was founded in 1978 and is based in London, the United Kingdom.